P

Palatin Technologies, Inc. (PTN)

NCM – Real vaqt narxi. Valyuta: USD

9.47

+2.04 (27.46%)

Yopilishda: Aug 12, 2026, 4:00 PM EDT

9.65

+0.18 (1.90%)

Bozordan keyin: Aug 12, 2026, 4:55 PM EDT

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Barcha huquqlar himoyalangan.

Foydalanish shartlari

P

Palatin Technologies, Inc. (PTN)

NCM – Real vaqt narxi. Valyuta: USD

9.47

+2.04 (27.46%)

Yopilishda: Aug 12, 2026, 4:00 PM EDT

9.65

+0.18 (1.90%)

Bozordan keyin: Aug 12, 2026, 4:55 PM EDT

06.08.2026

StreetWatch: A $2.9 Billion Takeover Put a Spotlight on Relentless Hunger. Palatin Technologies Is Developing the Next Generation of the Drug That Seeks to Treat It

Rare-endocrine buyers have paid roughly $2.9 billion and approximately $10.0 billion for acquisitions in this area over the past four months. IMCIVREE, the only approved MC4R agonist for acquired hypothalamic obesity and Bardet-Biedl syndrome, generated $71.3 million of global revenue during the second quarter of 2026, including $51.0 million in the United States and representing a 19% sequential quarter increase in global sales.

Videolar

No Data

There is no data to display

Press-relizlar

06.08.2026

StreetWatch: A $2.9 Billion Takeover Put a Spotlight on Relentless Hunger. Palatin Technologies Is Developing the Next Generation of the Drug That Seeks to Treat It

Rare-endocrine buyers have paid roughly $2.9 billion and approximately $10.0 billion for acquisitions in this area over the past four months. IMCIVREE, the only approved MC4R agonist for acquired hypothalamic obesity and Bardet-Biedl syndrome, generated $71.3 million of global revenue during the second quarter of 2026, including $51.0 million in the United States and representing a 19% sequential quarter increase in global sales.

Search stocks

Palatin Technologies, Inc. (PTN)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Palatin Technologies, Inc. (PTN)

StreetWatch: A $2.9 Billion Takeover Put a Spotlight on Relentless Hunger. Palatin Technologies Is Developing the Next Generation of the Drug That Seeks to Treat It

Videolar

No Data

Press-relizlar

StreetWatch: A $2.9 Billion Takeover Put a Spotlight on Relentless Hunger. Palatin Technologies Is Developing the Next Generation of the Drug That Seeks to Treat It